Kymera Therapeutics KYMR Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's cash ratio?
- Kymera Therapeutics (KYMR) reported cash ratio of 2.3× in Q1 2026.
- How has Kymera Therapeutics's cash ratio changed year-over-year?
- Kymera Therapeutics's cash ratio increased by 50.8% year-over-year, from 1.5× to 2.3×.
- What is the long-term trend for Kymera Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Kymera Therapeutics's cash ratio has grown at a 72.6% compound annual growth rate (CAGR), from 0.3× to 4.3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.